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Abstract
Atherosclerosis is regarded as one of the leading causes of mortality and morbidity in the world. Nowa-
days, it seems that atherosclerosis cannot be defined merely through the Framingham traditional risk
factors and that autoimmunity settings exert a remarkable role in its mechanobiology. Individuals with
autoimmune disorders show enhanced occurrence of cardiovascular complications and subclinical
atherosclerosis. The mechanisms underlying the atherosclerosis in disorders like rheumatoid arthritis,
systemic lupus erythematosus, antiphospholipid syndrome, systemic sclerosis and Sj€ogren’s syndrome,
seem to be the classical risk factors. However, chronic inflammatory processes and abnormal immune
function may also be involved in atherosclerosis development. Autoantigens, autoantibodies, infectious
agents and pro-inflammatory mediators exert a role in that process. Being armed with the mecha-
nisms underlying autoimmunity in the etiopathogenesis of atherosclerosis in rheumatic autoimmune
disorders and the shared etiologic pathway may result in substantial developing therapeutics for these
patients.
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INTRODUCTION
Atherosclerosis is a multifactorial disorder that starts
early in life and finally is clinically presented later in
life. This complication is primarily regarded as an
impairment in the immune system in association with
the vascular system. Isolation of immune cells such as
lymphocytes and macrophages from atherosclerotic les-
sons implies involvement of the immune system in the
etiopathogenesis of atherosclerosis.1,2 Inflammation
may exacerbate atherosclerosis through various
approaches after infectious diseases, autoimmunity and
other proatherogenic modifications during the inflam-
matory settings.
Autoimmune rheumatic diseases (AIRDs) have
been accompanied with increased risks of cardiovas-
cular-associated mortality and morbidity, mainly
after atherosclerosis events. This can be attributed to
traditional risk factors of atherosclerosis and therapy
with specific drugs like corticosteroids. Several AIRDs
are clearly associated with higher cardiovascular dis-
ease (CVD) as well as progression of subclinical
atherosclerosis, which may occur prior to the mani-
festation of clinical disease and, therefore, be a tar-
get of early diagnosis and preventive therapeutic
strategies.3,4
In this review article, we intend to go through the
findings about atherosclerosis and CVD events occur-
ring during AIRDs.
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IMMUNOPATHOGENESIS OF
ATHEROSCLEROSIS
Immune system cells are present in atherosclerotic
plaques, proposing that they play a role in the
mechanobiology of atherosclerosis. Infiltration of
immune cells to the plaque lesions as well as their acti-
vation can occur after several triggering factors like
immune response to infectious microbes.5 These
immune cells are believed to exacerbate atherosclerosis
progression, since depletion of CD4+ and CD8+ T cells
significantly declined the formation of fatty streaks in
C57BL/6 mice. Moreover, breading of mice with severe
combined immunodeficiency (SCID) and apolipopro-
tein E (ApoE)-knockout mice resulted in a 73% decline
in aortic fatty streaks in offspring in comparison to
mice with normal healthy immune systems. In addi-
tion, transferring of CD4+ T cells to immunodeficient
mice led to increased lesion areas.6 Thus, it is clear that
atherosclerosis has an autoimmune setting, in which
the immune cells within plaques release several cytoki-
nes, such as interleukins (IL), tumor necrosis factor
(TNF)-a, and platelet-derived growth factor (PDGF)
(Fig. 1).
During atherosclerosis development, a cellular
immune response specifically against oxidized low-
density lipoprotein (oxLDL), heat-shock proteins
(HSPs) and 2-glycoprotein-I (2GPI) has been identified,
implying the role of these molecules in atherosclerosis
processes.1 Atherosclerotic lesions obtained from caro-
tid endarterectomies possess 2GPI, which is highly
expressed within the intimal-medial border of human
atherosclerotic plaques and the subendothelial area.7
Upon engraftment of lymphocytes from 2GPI-immu-
nized LDL-receptor-deficient mice into syngeneic mice,
the host mice demonstrated aggravated fatty streaks in
comparison to mice obtaining lymphocytes from
healthy mice.8 T cells against 2GPI can worsen
atherosclerosis, proposing 2GPI as a autoantigen during
atherosclerosis development. It seems that several speci-
fic cell lines responding to specific antigens can modify
atherosclerosis through exacerbation or amelioration of
its procedure.
On the other hand, a number of autoantibodies has
been associated with increased risk of atherosclerosis
and its clinical picture. In an animal study, it was
observed that administration of anti-cardiolipin anti-
bodies to LDL-receptor-deficient mice led to elevation
of anti-cardiolipin production and increased atheroscle-
rosis lesions.9 Moreover, immunization of mice with
2GPI eventuated in intense cellular (CD4+ cells)
responses against 2GPI, as well as increased levels of
Figure 1 The balance of pro- and anti-atherogenic cytokine networks in atherosclerosis. IFN, interferon; IL, interleukin; MCP,
monocyte chemotactic protein; TGF, transforming growth factor; TNF, tumor necrosis factor.
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anti-2GPI antibodies that were accompanied with
aggravated atherosclerotic lesions.
Oxidized low-density lipoprotein is up-taken by
macrophages, which then are modified to foam cells
and develop atherosclerotic events. Anti-oxLDL anti-
bodies are seen in healthy individuals as well as in
AIRD patients with atherosclerosis.10 Among the evalu-
ations of various lipoproteins, anti-oxLDL autoantibod-
ies distinguished properly between patients with
peripheral vascular disorder and a control group. More-
over, there was a positive trend for increased autoanti-
body levels in subjects with more intense
atherosclerosis.11 In several AIRDs, including systemic
vasculitides,10 systemic sclerosis (SSc)12 and systemic
lupus erythematosus (SLE),12 the autoantibodies
against oxLDL were higher in comparison to controls.
Furthermore, a correlation was observed between the
level of antibodies to oxLDL and total immunoglobulin
levels in SLE patients, while there was no correlation
between the total immunoglobulin levels and antibod-
ies to other antigens. This issue demonstrates that there
is an increased total immunoglobulin level in patients
with SLE that is against to some specific antigens, such
as oxLDL.12
ATHEROSCLEROSIS IN AUTOIMMUNITY
Atherosclerosis and rheumatoid arthritis
Rheumatoid arthritis (RA) patients show declined life
expectancy and mortality ratios range from 0.87 to 3.0
compared with the healthy population.13 Studies have
reported that CVDs are responsible for main cause of
mortality in various cohorts of RA populations.13,14
Moreover, evidence implies that mechanisms underly-
ing increased CVD mortality in RA are not completely
understood.14 Various types of cardiac complications
have been reported in RA individuals. However,
ischemic heart disease occurring after atherosclerosis
appears to be the main reason of CVD-associated
deaths in RA cases.13,15 Cigarette smoking has been
known as a risk factor for RA onset and progression that
increases the disease severity and rheumatoid factor
levels in a dose-dependent manner.16 Nonetheless, sev-
eral researches could not determine smoking as a pre-
dictor of CVD-associated deaths in inflammatory
polyarthritis and seropositive RA.17 RA treatment
approaches and lifestyle of these patients may result in
hypertension, diabetes mellitus, physical inactivity and
obesity; however, evidence does not support clearly the
implication of such factors in the accelerated atheroscle-
rosis development in RA cases.13,15 As a frequently used
drug in RA treatment, methotrexate increases homocys-
teine levels in plasma, which has been recognized as a
new and modifiable risk factor for CVD development in
the general population.18 During therapy with
methotrexate treatment, continuous folate supplemen-
tation reduced homocysteine levels and declined CVD-
associated mortality in patients with RA.18 Findings
about the role of dyslipidemia in RA patients are incon-
gruous. However, more reliable data demonstrated that
an increase in small LDL and decreased high-density
lipoprotein (HDL) levels occurred after chronic inflam-
mation development rather than being a primary meta-
bolic modification in RA.13
Rheumatoid arthritis by itself confers a remarkable
risk factor for development of early atherosclerosis as
well as CVD.17 In this context, several researchers pro-
posed that impaired immune system and chronic
inflammation in RA play key roles in development of
accelerated atherosclerosis.13–15 Similar to the RA joint,
atherosclerotic lesions are manifested through overex-
pression of adhesion molecules as well as increased
cells secreting proinflammatory cytokines that infil-
trated to the plaques by responding to chemoattractant
mediators released by locally activated endothelia. It
seems that collagen-degrading mediators are involved
in destabilization of atherosclerotic plaques and carti-
lage and bone erosion of the joints in RA patients. As a
result, it can be concluded that the chronic and systemic
inflammation in RA may induce early events and hence,
development of accelerated atherosclerosis. Redundant
cardiovascular-related mortality occurs frequently in RA
patients alongside with more widely diffuse and sys-
temic complications, which may manifest through vas-
culitis and lung involvement.19
Despite this observation of rheumatoid vasculitis
having a role in developing atherosclerosis, there is evi-
dence proposing that vessel dysfunction is an important
event during early endothelial damage in RA cases.
Endothelial dysfunction has been observed in some
cohort studies of RA patients, unrelated to age of
patients, disease duration, disease activity levels and
seropositive status.20,21 Although various factors could
modify the mechanobiology of the endothelium, accu-
mulating lines of evidence provide the view that
endothelial dysfunction in RA patients is substantially
associated with inflammation. It was observed that
abnormal function of endothelium in young RA
patients with low disease activity was predicted via C-
reactive protein (CRP) and LDL levels. Chronic abnor-
mal function of endothelium causes susceptibility to
vascular wall damage, which can be diagnosed through
910 International Journal of Rheumatic Diseases 2018; 21: 908–921
M. Sanjadi et al.
carotid intima-media thicknesses (IMT) during the pre-
clinical stage, prior to clear disease manifestation. A
bulk of studies have reported enhanced carotid IMT in
RA patients.22–24 However, this observation could not
be justified by corticosteroid therapy but seems to be
relevant to systemic inflammation manifestations and
disease duration, assigning a role for RA as a risk factor
for atherosclerosis development. As an immunological
factor exerting a common pathogenic player in both RA
and atherosclerosis, a specific category of CD4+ T cells
(CD4+ CD28null T cells) has attracted highlighted con-
cern. After stimulation via endothelial autoantigens pre-
sent in the peripheral blood of RA patients with
unstable angina pectoris, CD4+ CD28null T cells are
expanded.24 In addition, these cells infiltrate into the
atherosclerotic plaques and exhibit a proinflammatory
phenotype with the potential of damaging tissue, which
mediates vascular injury.25 It has been shown that
CD4+ CD28null T cells exert a contributory role in early
development of atherosclerosis in RA patients. RA
patients with increased proliferation of CD4+ CD28null
T cells show an enhanced level of abnormal endothelial
function as well as increased carotid IMT in relation to
RA patients lacking proliferation of these cells.232
Atherosclerosis and SLE
Systemic lupus erythematosus is a chronic autoimmune
disorder that affects several organs and exhibits a wide
spectrum of clinical presentations. Young women are
predominantly affected with SLE, which generally does
not demonstrate atherosclerosis development.
Nonetheless, CVDs have been reported to be an impor-
tant cause of mortality and morbidity in patients with
SLE.26 In SLE patients, coronary artery disease has been
reported with a prevalence of 6–10% and the develop-
ment risk 4–8 times higher in relation to the normal
population.27,28 As well, 3–25% of deaths in SLE
patients has been reported to have underlying acute
myocardial infarction.26,29 In a bimodal study describ-
ing the death causes due to SLE, it was demonstrated
that early causes were associated with SLE itself or infec-
tions, and late causes were mediated by CVD.30 Further-
more, substantial atherosclerotic complications were
seen in over 50% of fatalities in postmortem studies but
were unrelated to the cause of death.31 Atherosclerosis
has frequently been reported in SLE patients in compar-
ison to the general population, and it represents acceler-
ated development in both SLE and diabetes mellitus
patients.27,28
Despite atherosclerosis development being frequently
observed early in the course of SLE, later age occurrence
appears to be the main atherosclerosis determinant in
these patients.27,28 In addition, the average count of
changeable traditional risk factors about atherosclero-
sis, such as arterial hypertension, hypercholesterolemia
diabetes mellitus, smoking and obesity, is higher in SLE
patients in relation to the normal population.32 Clinical
studies on atherosclerosis demonstrated that older age
at disease diagnosis, hypertension and hypercholes-
terolemia were the traditional risk factors predicting
clinical manifestations.27,28,33 Nonetheless, Framing-
ham risk factors, including age, sex, LDL, HDL and
blood pressure, cannot explain atherosclerosis, which
has been attributed to complicated interactions
between traditional risk factors and factors related to
the disease per se or its therapies. Cumulative dosage
and prolonged corticosteroid treatment as well as
longer disease duration are nontraditional risk factors
that probably are the major predictors of atherosclerosis
in SLE patients.27,28 Some recently identified risk factors
contributing to atherosclerosis development are
immunological factors such as anti-cardiolipin, anti-
oxLDL, anti-2GPI, anti-HSP antibodies, inflammatory
markers such as fibrinogen, CRP, inteleukin (IL)-6,
CD40/CD40L, adhesion molecules, coagulation factors,
such as plasminogen activator inhibitor-1 (PAI-1) and
homocysteine. Researchers trying to identify diagnostic
approaches are able to disclose an increased prevalence
of cardiovascular lesions, since they potentially identify
subclinical atherosclerosis.
Impaired mechanobiology of the coronary circulation
has been observed in 40% of patients with SLE34 that
could be even higher.35 Calcifications of the coronary
artery were identified in 31% of SLE patients and were
significantly increased in SLE patients in comparison to
control subjects.36 The most frequently used approach
for the diagnosis of subclinical atherosclerosis is
through carotid B-mode ultrasound, which detected
carotid plaques in 17–65% of SLE patients.37–41 That
notwithstanding, carotid ultrasound directly examines
only the carotid artery; this method supplies a precise
evaluation of subclinical atherosclerosis.
The examination of risk factors for clinical atheroscle-
rosis seems to be difficult in SLE since the cardiovascu-
lar complications are less frequently detected due to
low SLE prevalence. The investigation of subclinical
atherosclerosis has the benefit of sullying an increased
number of lesions, resulting in suitable measurement of
risk factors. A study demonstrated that focal atheroscle-
rotic plaques were as frequent as 40% out of 175 SLE
women, as diagnosed by B-mode ultrasound. Moreover,
the study detected a negative correlation between
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disease activity and plaques.37 By ultrasound approach
for detecting the common carotid artery in 26 SLE
patients with previous history of CVDs, SLE patients
without previous history CVD, and 26 healthy control
cases, plaques were identified in 65% of SLE cases with
CVD, 38% of SLE subjects without CVD, and 11% of
the healthy control cases.38 Among the items identified
more frequently in SLE cases with CVD in comparison
to SLE patients without CVD that were associated with
CVD were lupus anticoagulant, increased steroid cumu-
lative dosage, osteoporosis-increased triglyceride levels,
1-antitrypsin, oxLDL, anti-oxLDL, lipoprotein(a),
homocysteine and low HDL levels.
In a case–control study applying carotid ultrasound,
plaques were found in 37% and 15% of SLE patients
and healthy control, respectively.39 It was demon-
strated that two factors were associated with plaques
using the multivariate analysis of risk factors, namely
age and SLE diagnosis. On the other hand, factors
associating with plaques in SLE patients were longer
duration of disease, older age at diagnosis, higher
damage-index score, anti-Sm antibody absence, and
no use of hydroxychloroquine and cyclophosphamide.
It was suggested that attenuated disease severity and
therefore, low administration of immunosuppressive
drugs increased the risk of plaque development.
Nonetheless, the patients with less severe disease activ-
ity were older than patients with high disease inten-
sity. Thus, the higher prevalence of plaques in this
group could be related not to milder disease but
rather to age itself, a factor not considered by the
authors in the multiple regression analysis for disease-
related factors. On the other side, in a study evaluat-
ing female SLE cases without CVD, plaques were iden-
tified in 32% of patients and determinants of plaques
were higher systolic blood pressure, lower HDL levels,
use of antidepressants and older age.41
In research to prospectively evaluate the implications
of the traditional and nontraditional factors related to
subclinical atherosclerosis in SLE patients without CVD,
the intima was found to be thickened in 28% of
patients and plaques were identified in 16.6% of them.
Moreover, age and cumulative prednisone intake were
found to be associated with abnormalities in the carotid
artery. It seems that an interaction between traditional
risk factors, most importantly age, and nontraditional
risk factors, particularly cumulative prednisone intake,
could be associate with atherosclerosis in SLE
patients.40 As a predictor of atherosclerosis, age of cases
appeared to be of greater importance in SLE patients
compared with the general population. This may stem
from adverse effects in older patients due to disease
severity and treatment.
Atherosclerosis and SSc
Systemic sclerosis mainly affects the microcirculation
and also microvascular endothelial cells, which lead to
blood vessel obstruction and tissue anoxia.42 Further-
more, SSc considerably accelerates the endurance of the
vessel wall of the macrocirculation, raising the risk of
vascular obstructive disorder.43 The relationship
between atherosclerosis and SSc was first elucidated in
some SSc patients who experienced lower limbs ampu-
tation due to peripheral macrovascular disorder.44 Four
patients with SSc were described with extensive
macrovascular involvement of the lower limbs. How-
ever, the ulnar artery biopsy demonstrated a distinct
vessel narrowing without plaques in these patients.43 In
limited cutaneous SSc (lSSc), macrovascular disorder
was identified in 58% of patients (18 of 31 patients),
and 16% (five patients) of patients underwent lower
limbs amputation. Biopsies demonstrated severe inti-
mal thickening, extensive proliferation with degenera-
tion of the internal elastic lamina, and plasma cellular
and transmural lymphocytic infiltrate.45 In 10 of 53 SSc
patients, 6.5% had cerebrovascular disease, 15.2% coex-
istent ischemic heart disease and 21.7% intermittent
claudication (21.7%).44 The study by Soriano et al. of
the main arteries of the abdomen, limbs and neck,
showed that initially the ulnar artery was obstructed,
which was ascertained by angiography in 15 patients
and subtraction angiography in nine of 26 SSc patients.
Angiography detected lower-limb involvement and also
a raised stiffness of the radial artery.46 In approximately
64% of SSc patients versus 35% of healthy subjects, the
carotid artery was affected.45 In addition, the involve-
ment of the carotid artery was identified in 53 SSc
patients.47 The evaluation of IMT in the common caro-
tid artery by ultrasound showed significant increase.
The IMT was significantly correlated with the existence
of the D allele of the angiotensin-converting-enzyme
(ACE) gene, which facilitates atherosclerosis.45 The
increased frequency of the D allele significantly corre-
lates with the incidence of SSc.48 These studies propose
that considerably higher IMT and deletion/deletion
(DD) or insertion/deletion (ID) variants of ACE gene
are associated and increase the risk of macrovascular
involvement in SSc.
In diffuse SSc the involvement of vessel network
broadens from the microcirculation to the macrocircu-
lation. The diffuse involvement of the vascular tree
could be related first with two factors: the tendency of
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the single case to atherosclerosis and disease pathogene-
sis. These two key factors can be synergized, thus affect-
ing the integrity of the vessel network. In genetically
susceptible SSc cases, determined by increased levels of
LDL in oxidation state, oxidative stress and ischemia,49
vessel wall inflammation and fibrosis are induced,50
which eventually leads to SSc-associated vascular
endothelial damage and finally generates a noxious
loop involving the macrocirculation and microcircula-
tion. In this situation, pathogenetic elements contribut-
ing to endothelial destruction, including dysfunction of
the coagulation and fibrinolytic system, anti-endothe-
lial cell antibodies, soluble intercellular adhesion mole-
cule-1, CRP, and a rise of serum levels of homocysteine,
may significantly promote the risk of accelerated
macrovascular disorder.51–53 From the therapeutic per-
spective, the vessel wall protecting agents, such as
antioxidants and statins,54,55 might become a possible
options for the management of macrovascular and
microvascular involvement in SSc patients. Overall, the
extent of increased risk of atherosclerosis in SSc is not
yet fully clear. Further studies are needed to address this
specific question.
Atherosclerosis and Sj€ogren’s syndrome
Sj€ogren’s syndrome (SS) is a heterogeneous systemic
autoimmune disorder determined by chronic lympho-
cyte infiltration of exocrine gland tissues and autoanti-
body production. The common manifestation of SS is
highlighted by systemic organ involvement including
nervous system, gastric, musculoskeletal, renal and pul-
monary diseases. Furthermore, sicca syndromes fre-
quently have been reported is SS patients. However,
cardiac muscle involvement is very rare among SS
patients. In a recent study, evaluation of SS patients and
those with SS secondary to SLE, none of them had car-
diac involvement.56 Moreover, the association between
atherosclerotic plaque expansion and the occurrence of
secondary SS in RA and SLE patients did not reach a sta-
tistically significant threshold.57
There are some case report studies that demonstrated
the occurrence of cardiac stroke among young patients
with primary SS. Nevertheless, those cardiac strokes
were mostly associated with vasculitis and not attribu-
ted to accelerated atherosclerotic plaque develop-
ment.58,59 It has been reported that patients with
primary SS were identified as having lower circulating
anti-lipoprotein lipase autoantibodies compared with
SLE or RA patients and healthy individuals. These speci-
fic autoantibodies have been related to increased levels
of triglycerides in serum and probably an elevated risk
of atherosclerosis.60 Taken together, the number of
studies evaluating the risk and incidence of atheroscle-
rosis between primary SS patients is not adequate. Thus,
we propose that further studies are warranted to assess
atherosclerosis susceptibility among primary SS
patients.
THERAPEUTIC APPROACHES
Therapeutic strategies (Fig. 2) for arthrosclerosis and
other CVDs should be managed according to the clini-
cal manifestation.61 Many patients who are susceptible
to thrombosis and vascular occlusion, such as antiphos-
pholipid syndrome and SLE patients, are prescribed
aspirin which can reduce the possibility of vascular
thrombosis, beyond the pro-coagulant activity of
autoantibodies and underlying mechanisms, the
increased arthrosclerosis development characterizing
these diseases.62 Still, the key point primarily should be
that the best therapeutic approach is prevention.63 In
patients with autoimmune disorders the risk of
arthrosclerosis and other CVDs are increased not only
because of the autoimmune state, but also due to dis-
ease consequences, such as nephritis, which lead to
nephrotic syndrome and hypertension, as well as drugs
such as steroids.64 In addition, other possible risk fac-
tors should be elucidated in autoimmunity. In patients
with SLE, increased levels of very LDL cholesterol,
triglycerides, and homocysteine and also decreased
levels of apoA-1 and HDL cholesterol have been
described.65,66 Accordingly, atherosclerosis patients
should take preventive therapy based on instructions
for blood pressure control, regular exercise, and when
the usage of folic acid and statins is necessary.67
Immunomodulation of atherosclerosis is an interesting
option, although it is still in the infancy stage.68
Immunomodulation approaches have been developed
based on several methods, including immunosuppres-
sion, use of intravenous immunoglobulins (IVIg),
induction of oral tolerance with autoantigens (for
instance oxLDL), cytokine inhibitors, gene therapy and
bone-marrow transplantation.
Vaccination against atherosclerosis?
The finding of atheroprotective immunity has shed a
new light on the possibilities for immunoprevention or
immunotherapy.69 The application of atherosclerosis-
related antigen should specifically induce those effective
T cell-dependent antibodies that operate to decrease
atherogenesis.70 At least theoretically, atheroprotective
immunity should be induced without activation or
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interference of other elements of the immune system.
The principle explanation behind preventive immunity
in atherosclerosis is to promote a specific immune
response that would decrease the progression of
atherosclerosis.71 In murine models of atherosclerosis,
immunization with modified epitopes of LDL led to
decreases in atherosclerosis lesions.70,72 These data
determine that the humoral immune response against
oxLDL is protective.73 Furthermore, immunization with
oxLDL also led to decreased neo-intimal formation fol-
lowing balloon damage.73 However, the findings of dif-
ferent studies about the importance of oxLDL
antibodies in association or prediction of atherosclero-
sis are inconsistent and inconclusive. The increased
levels of anti-oxLDL antibodies were predictive of mor-
tality, myocardial infarction occurrence and carotid
atherosclerosis progression.74 The autoantibodies direc-
ted against oxLDL are likely belong to two separate
families of antibodies.75 On one side, ‘pathogenic’
antibodies increase atherosclerosis progression and
significantly correlate with atherosclerotic plaque
formation.76 On the other side, immunization with
oxLDL could stimulate the production of autoantibod-
ies directed against large particle antigens, which play
atheroprotective rather than atherogenesis roles in
atherosclerosis.77 These particular antibodies can oper-
ate as promoting the clearance of the antigen–autoanti-
body complex rather than increasing its deposition in
the arterial intima.71 The development of monoclonal
antibodies against specific epitopes of oxLDL, have
shown that these monoclonal antibodies could inhibit
the uptake of oxLDL by macrophages. In addition, anti-
oxLDL antibodies could inhibit the uptake of apoptotic
cells by macrophages.78 In Watanabe hyperlipidemic
rabbits, the study by Palinski et al. described that par-
enteral vaccination with oxLDL particles decrease
atherosclerosis.79 Subsequently, in fat-fed NZ White
rabbits, LDL receptor (ldlr)/ mice and ApoE/ mice
similar results were reported.72,79 Thus, these results
illustrated that atheroprotective immunity can be
achieved by vaccination. It seems that this active immu-
nization operates through humoral as well as cellular
Figure 2 Therapeutic targets and potential target genes in treatment of atherosclerosis in autoimmune rheumatic disease patients.
ABCA1, adenosine triphosphate-binding cassette transporter 1; Apo A1, apolipoprotein A1; CCR, C-C chemokine receptor; Ec-
SOD, extra-cellular superoxide dismutase; ICAM, intracellular adhesion molecule; IL, interleukin; LCAT, lecithin cholesterol acyl-
transferase; LDL, low-density lipoprotein; MCP, monocyte chemotactic protein; NOS, nitric oxide synthase; PAF-AH, platelet-acti-
vating factor acetylhydrolase; TIMP, tissue inhibitor of metalloproteinase; TNF, tumor necrosis factor; VCAM, vascular cell
adhesion molecule.
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immunity and protection is achieved by secretion of
natural IgM antibodies against phosphocholine and as
well as T cell-dependent IgG antibodies against
oxLDL.80 in particular, active immunization with
oligopeptides of the ApoB100 also modulates
atherosclerotic plaque formation.81 This specific manip-
ulation in the immune system generally leads to activa-
tion of antigen-specific T helper cells by presentation of
antigen through the major histocompatibility complex
class II pathway. Accordingly, the possible contribution
of T helper cell responses in atheroprotection can be
deduced. However, it should be elucidated whether T
helper cell responses operate via induction of high-titer
antibodies against oxLDL or by immunoregulatory
loops, which are mediated through Treg cells. In any
event, up to now immunization data are promising and
further efforts should be made in development of effec-
tive vaccines against atherosclerosis.
Immunosuppression
When atherosclerosis is attributed to an immunological
process, it is essential to demonstrate whether this
active immunological process leads to or instead pro-
tects from atherosclerosis. Another scenario is also pos-
sible, as in terms of disease or health statuses, both
activities of the immune response could be happening
in atherosclerosis; in other words it is a double-edged
sword. Limited data emphasize this scenario. The treat-
ment of C57BLy6 mice with cyclosporin A (an
immunosuppressive agent) led to accelerated
atherosclerosis, which suggests a preventive function of
T cell-mediated response at the fatty streak stage.82 Para-
doxically, the depletion of CD4+ and CD8+ T cells
decreased fatty streak formation in C57BLy6 mice, rep-
resenting the aggravated role of T cells in fatty streak
formation.83 The offspring from the cross of immunod-
eficient scid/scid mice with ApoE knockout mice had a
73% decrease in aortic fatty streak lesions formation
compared to healthy control mice.84 The transfer of
CD4+ T cells from immunocompetent to the immunod-
eficient mice, led to 164% increase in fatty streak
lesions formation.84 This finding was associated with
transferred T cells into the atherosclerosis lesions.
Another study also pointed to the influence of T cells in
atherosclerosis: the intraperitoneal transfer of lympho-
cytes from LDL receptor-deficient mice which were
immunized with b2-glycoprotein-1 into syngeneic mice
lead to the formation of larger fatty streak lesions in the
recipients mice, compared with mice that were trans-
ferred with lymphocytes from healthy control mice.8
The depletion of T cells from whole lymphocyte
populations failed to induce fatty streak lesions. There-
fore, b2-glycoprotein-I reactive T cells play a critical role
in atherosclerotic plaque formation and immunosup-
pression could be a more interesting option in the treat-
ment of atherosclerosis. The infiltrated leukocytes in
atherosclerotic plaques express CD40 and CD40 ligand
molecules. In LDL receptor-deficient mice, the treat-
ment with anti-CD40 ligand antibody significantly
modulates atherosclerotic plaque formation.85 These
findings propose that depletion of T cell populations
and/or inhibition of T cell responses could help to
reduce atherosclerosis. This situation also occurs in
cytotoxic agent administration during bone marrow
transplantation or cancer therapy. Nevertheless, the
problem is considerably more complicated, because
these specific antibodies not only predispose us to
infections but also have noxious effects on the vascular
wall components that could facilitate atherosclerosis
progression. Thus, the real consequence of immuno-
suppression might be even progression of atherosclero-
sis instead of inhibition.
Induction of tolerance
Beyond the role of oxLDL particles in immunization,
intervention in mice at earlier stages with this antigen
might induce tolerance.86 In the study by Nicoletti et al.
the intervention of newborn ApoE knockout mice with
oxLDL and a high-cholesterol diet lead to decrease of
the immune response against oxLDL and also
atherosclerosis susceptibility in mice.87 The interven-
tion with oxLDL lead to clonal deletion and T cell toler-
ance instead of T cell anergy.
Intravenous immunoglobulin
Intravenous immunoglobulins which is prepared from
serum immunoglobulins of numerous donors is mainly
composed of the IgG isotype. It has several indications,
including autoimmune diseases, alloimmune thrombo-
cytopenia, idiopathic thrombocytopenic purpura, Guil-
lain–Barre syndrome and various immunodeficiency
states.88 Because atherosclerosis is an active immunologi-
cal process, IVIg containing anti-idiotypic antibodies and
natural antibodies could modulate the atherosclerosis
process.89 Hence, inoculations of 49-day-old ApoE
knockout mice with IVIg for 5 days significantly
decreased fatty streak lesion formation by 35% in about
60 days.90 Moreover, the inoculation of mice with IVIg,
significantly decreased fibrofatty lesions induced by
4 months of regime treatment. Therefore, IVIg was
reported be effective not only during plaque formation,
but also during fatty streak lesion formation in
International Journal of Rheumatic Diseases 2018; 21: 908–921 915
Atherosclerosis and autoimmunity
atherosclerosis.90 Finally, IVIg therapy induced the inac-
tivation of lymph nodes and spleen T cells, and led to a
significant decrease in anti-oxLDL IgM antibodies.91
Gene therapy
Gene therapy is a potential new strategy to target several
factors participating in progression and development of
atherosclerosis. Several genes that participate in the pro-
gression of atherosclerosis have been recognized and
have been evaluated as potential new options for ther-
apy92 (Fig. 1). The importance of using gene therapy to
modulate immune responses actually depend on specif-
ically targeting the expression of adhesion molecules on
the vascular wall and chemokines to affect the progres-
sion of atherosclerosis. In humans, there are few clinical
trials of gene therapy for different cardiovascular disor-
ders. Several vector systems for gene therapy in CVD
have been developed (Table 1). Retroviral-mediated
vector of the encoding LDL receptor gene to the liver of
familial hypercholesterolemia patients was effectively
delivered, although LDL levels remained raised.93
Another study about a phase 1 clinical trial of intra-
muscular delivery of VEGF (vascular endothelial growth
factor) encoding vector in the severe peripheral vascular
disease milieu has been conducted. The delivery of
VEGF encoding vector was implemented in 10 organs
in nine cases suffering from non-healing ischemic foot
ulcers. In that study the elevated levels of circulating
VEGF and subsequently, objective evidence of
improved distal flow in limbs was described.94 In some
of the patients where conventional therapy was not
effective, the direct delivery of VEGF plasmid into the
myocardium was conducted and significant improve-
ment in angina and also reduced ischemia was reported
in all patients.95,96 Furthermore, similar findings were
obtained within adenoviral base vector for delivery of
VEGF to ischemic myocardium.96
Cytokine network manipulation
The cellular components of atherosclerotic lesions, like
autoimmune diseases, secrete numerous inflammatory
cytokines including TNF, PDGF, interferon (INF)-c,
IL1, IL-2, IL-6, IL-8 and IL-12.97 Accordingly, several
studies have been designed to inhibit the detrimental
effect of these cytokines in atherosclerosis and they pro-
vide an effective approach for treatment of atherosclero-
sis98 (Fig. 2). Fortunately, in some of them encouraging
results have been reported. In a cohort study of 130
elderly man, there was a significant association between
circulating TNF-a levels and atherosclerotic plaque for-
mation.99 Vascular calcification is an ectopic phe-
nomenon that usually happens in atherosclerosis.100
TNF-a within atherosclerotic plaque lesions also con-
tributes to bone formation. It has been shown that
treatment of bovine aortic smooth muscle cells (which
are able to stimulate osteoblastic differentiation) with
Table 1 Vector systems for gene therapy of cardiovascular disease
Vector Advantages Disadvantages
Adenovirus Transduce dividing and nondividing cells
High-level expression
Relatively easy to produce to high titer
Nonintegrating
Large transgene capacity
Short-lasting expression
Host immune and inflammatory reactions
Adeno-associated
virus
Transduce dividing and nondividing
Cells
Nonpathogenic
Low immunogenicity
Integrating
Long-lasting and stable transgene expression
Limited transgene capacity
Risk of insertional mutagenesis due to random integration
Laborious production procedure
Lentivirus Transduce dividing and nondividing
Cells
Low immunogenicity
Integrating
Long-lasting and stable transgene expression
Relatively low transfection efficiency
Risk of insertional mutagenesis
Laborious production procedure
Retroviruses Low immunogenicity
Integrating
Transduce only dividing cells
Low efficiency
Liposomes Nonpathogenic
Easy to produce
Poor efficiency
Transient expression
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TNF-a led to morphological alterations into osteo-
blast-like cells.101 Moreover, they raised the expression
of matrix mineralization and alkaline phosphatase as
evaluated by incorporation of calcium into the matrix.
In particular, pretreatment of bovine aortic smooth
muscle cells with KT5720 (protein kinase A specific
inhibitor) reduced TNF-a-induced mineralization and
cell morphology.101 This finding recommends that
TNF-a inhibition might attenuate calcification of
atherosclerosis. Targeting of other cytokine families
also has a critical role in modulation of atherosclero-
sis. In a rat model of the carotid artery, decrease in
transforming growth factor (TGF)-b levels through
ribozyme oligonucleotide targeting of the TGF-b gene
led to a substantial suppression of neointimal forma-
tion after vascular damage.102 This suppression of
neointimal formation was associated with significant
decrease of collagen synthesis.102 Furthermore, ApoE
and INF-c knockout mice (double knockout) had a
considerable reduction in the size of atherosclerotic
lesions, compared to ApoE wild type mice.103 A sub-
stantial reduction in lesion cellularity and lesion lipid
accumulation was described. However, collagen con-
tent of lesions was elevated.103 In mice with the INF-c
knockout gene, a significant elevation in atheroprotec-
tive particles including phospholipid/ApoA-IV has
been shown.104 Thus, INF-c promotes atherosclerosis
by systemic as well as local modification of plasma
lipoproteins and the arterial wall, respectively.105 By
applying the immunodeficient mouse model, it has
been shown that INF-c can trigger atherosclerotic
modifications in the absence of competent immune
response. This process is conducted through vascular
smooth muscle cells to trigger growth-factor-stimu-
lated mitogenesis.106 IL-8, as an inflammatory and
chemotactic cytokine, stimulates the proliferation and
migration of smooth muscle cells as well as vascular
endothelial cells.107 It has been reported that
increased baseline IL-8 plasma levels are related with
an elevated susceptibility of long-term all-cause com-
plications in cases with acute coronary syndrome.108
Moreover, it has been elucidated that in acute coro-
nary syndrome, IL-8 via its angiogenic properties, may
contribute to atherosclerotic plaque formation.108 The
IL-8 receptor, C-X-C chemokine receptor (CXCR)2 is
highly expressed on macrophages within atheroscle-
rotic plaque lesions.109 In mice with CXCR2 defi-
ciency, the progression of accelerated atherosclerosis is
significantly decreased; hence, it is possibly a pro-
atherogenic factor.110
Statins as immunomodulators
Human leukocyte antigen (HLA)-II molecules have a
key role in T lymphocytes activation and immune
response hemostasis. Statins directly inhibit IFN-c-
induced expression of HLA-II, and therefore act as a
direct inhibitor of HLA-II-mediated T cell activation.111
This effect of statins is mediated by suppression of the
inducible promoter IV of the HLA-II transactivator
CIITA, which is found in different cells of the immune
system, such as monocyte and endothelial cells.112 The
results of this study provide a defined mechanism for
the use of statins in the treatment of atherosclerosis.
CONCLUSION
Accelerated and early atherosclerosis is a distinct fea-
ture of some inflammatory and autoimmune disorders
due to more specific autoimmune mechanisms and
persistent inflammation. SLE and RA carry an elevated
susceptibility to atherosclerosis. In addition, SLE and
RA are highlighted by dominance of typical risk fac-
tors for coronary artery disorders and an elevated risk
of these disorders as well as an increased incidence of
subclinical atherosclerosis. However, in SSc and SS
patients, while there is a high frequency of macrovas-
cular disorders, the extent of increased risk of
atherosclerosis in these conditions is not yet fully
determined. Moreover, still no data exist to validate
elevated atherosclerosis in SSc and SS. The under-
standing of atherosclerosis as an active immune-asso-
ciated and autoimmune process is of critical
significance, not only for perception of its etiology
and pathogenesis, but also to facilitate the develop-
ment of effective therapeutic and preventive agents.
Up to now, most research is primarily in animal
models to modulate the development of atherosclero-
sis through the immune response. Therefore, it is
rational that applying the same strategies (cytokine
network manipulation, induction of tolerance, IVIg,
active immunization and immunosuppression) which
have been used in the treatment of autoimmune dis-
eases, maybe effective in modulation or prevention of
atherosclerosis. The human application of these strate-
gies and their substitutes in reduction of morbidity
and mortality, would be an immense achievement in
medicine.
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